Fundraise for OCRA and Support Cancer Research
Fundraise for OCRA
OCRA Heroes across the country are raising awareness and critical funds for OCRA’s research, advocacy, and patient support programs. Become an OCRA Hero by turning your passion into purpose to help make a difference in the fight against ovarian and related gynecologic cancers.
Upcoming Events
Attending an OCRA signature fundraiser or an event benefiting OCRA near you is a great way to support those facing ovarian and all gynecologic cancers and meet new people who share your passion, all while raising crucial funds for research, advocacy, and programs.
Start Fundraising
Become an OCRA Hero
Create a Fundraising Page
Ovarian Fitness Fundraisers
Create a Memorial Page
Fundraiser Guidelines
Create a Facebook Fundraiser
We can help support OCRA by creating fundraisers, volunteering and donating. Every single penny counts when we have such a long way to go.
– Mugdha
Related Topics
OCRA President & CEO Audra Moran Named Crain’s 2026 Notable Leader in Health Care
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued